Griesemer Chiropractic, LLC
Griesemer Chiropractic, LLC was paid $3.24M by Medicaid between Jan 2018 and May 2024, across 42 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 26% of everything it billed.
33Billing provider infoGRIESEMER CHIROPRACTIC, LLC
GREENWOOD, IN 46142
GREENWOOD, IN 46142
33aNPI1598953317assigned 10/05/2007
33bProvider typeChiropractor
28Total paid$3.24M
24GClaims91,339
24DCodes billed42
24AFirst – last monthJan 2018 – May 2024
Compared with peers
Next to other Chiropractor providers in Indiana
Rank by total paid#2 of 358
Median peer was paid$92K
This provider vs. median35×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,211 | $329K | |
| 2019 | 15,962 | $642K | |
| 2020 | 19,447 | $524K | |
| 2021 | 14,899 | $656K | |
| 2022 | 12,387 | $630K | |
| 2023 | 8,226 | $355K | |
| 2024incomplete | 2,207 | $106K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 26% | 28,409 | 24,333 | $828K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 23% | 17,198 | 14,828 | $738K |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 22% | 9,881 | 6,726 | $719K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.5% | 10,990 | 9,126 | $309K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 8.5% | 11,619 | 10,517 | $277K |
| 76942 | 2.9% | 3,221 | 2,685 | $94K | |
| 27096 | 1.9% | 1,664 | 1,392 | $63K | |
| 20552 | 1.9% | 3,137 | 2,581 | $62K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 1.9% | 113 | 110 | $61K |
| 80361 | <1% | 966 | 860 | $26K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 416 | 367 | $18K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 854 | 516 | $10K |
30 more codes
| 72110 | <1% | 365 | $8K | |
| 64483 | <1% | 52 | $5K | |
| 20611 | <1% | 106 | $3K | |
| 72170 | <1% | 251 | $3K | |
| 93923 | <1% | 52 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 85 | $2K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 267 | $2K |
| 64493 | <1% | 79 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 23 | $2K |
| 95923 | <1% | 15 | $1K | |
| 95924 | <1% | 16 | $1K | |
| 64484 | <1% | 26 | $657.70 | |
| 82962 | <1% | 918 | $648.52 | |
| 80347 | <1% | 24 | $614.11 | |
| 72050 | <1% | 25 | $494.79 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 14 | $415.28 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 73 | $388.28 |
| 64494 | <1% | 41 | $284.93 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 133 | $265.50 |
| 64495 | <1% | 35 | $180.30 | |
| 96132 | <1% | 16 | $147.73 | |
| 20610 | <1% | 25 | $128.58 | |
| 96130 | <1% | 16 | $113.97 | |
| 93040 | <1% | 16 | $78.41 | |
| 80326 | <1% | 12 | $67.50 | |
| 96138 | <1% | 16 | $50.76 | |
| 80349 | <1% | 13 | $33.75 | |
| 80352 | <1% | 13 | $33.75 | |
| Q4177 | Floweramnioflo, 0.1 cc | 0% | 130 | $0.00 |
| 80365 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRIESEMER, MARK (DOCTOR, MEMBER, MANAGER)